DDX43基因与肿瘤

doi:10.3760/cma.j.issn.1673-422X.2015.02.009

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (2): 115-117.doi: 10.3760/cma.j.issn.1673-422X.2015.02.009

DDX43基因与肿瘤

陈芹,林江,钱军

212002 镇江，江苏大学附属人民医院中心实验室

出版日期:2015-02-08 发布日期:2015-02-02
通讯作者: 钱军 E-mail:qianjun0007@sina.com
基金资助:
国家自然科学基金(81172592、81270630)；江苏省“333工程”科研项目（BRA2013136）；镇江市科技支撑社会发展项目（SH2013082）；江苏大学2012年度医学临床科技发展基金（JLY20120011、JLY20120013）；镇江市医学重点人才项目

DDX43 gene and tumors

Chen Qin, Lin Jiang, Qian Jun

Laboratory Center, Jiangsu University Affiliated People′s Hospital, Zhenjiang 212002, China

Online:2015-02-08 Published:2015-02-02
Contact: Qian Jun E-mail:qianjun0007@sina.com

摘要/Abstract

摘要： DEAD盒多肽43（DDX43）基因在肿瘤细胞恶性增殖、肿瘤细胞耐药及肿瘤免疫治疗方面发挥着重要作用。DDX43基因在多种实体瘤和某些血液系统恶性肿瘤中表达增高。DDX43基因启动子低甲基化出现于慢性髓系白血病、急性髓系白血病和骨髓增生异常综合征，并且与DDX43高表达和疾病的预后相关。

关键词: 肿瘤, 基因表达, 甲基化, DEAD盒多肽43

Abstract: DEAD (AspGluAlaAsp) box polypeptide 43 (DDX43) plays an important role in the malignant proliferation, drug resistance of tumor cells as well as neoplasm immunotherapy. The overexpression of DDX43 has been found in various solid tumors and some hematologic malignancies. The hypomethylation of DDX43 gene promoter is identified in chronic myeloid leukemia, acute myeloid leukemia and myelodysplastic syndrome, which is correlated with DDX43 overexpression and the prognosis of these diseases.

Key words: Neoplasms, Gene expression, Methylation, DEAD (AspGluAlaAsp) box polypeptide 43

陈芹,林江,钱军. DDX43基因与肿瘤[J]. 国际肿瘤学杂志, 2015, 42(2): 115-117.

Chen Qin, Lin Jiang, Qian Jun. DDX43 gene and tumors[J]. Journal of International Oncology, 2015, 42(2): 115-117.

参考文献

［1］ Martelange V, De Smet C, De Plaen E, et al. Identification on a human sarcoma of two new genes with tumorspecific expression［J］. Cancer Res, 2000, 60(14): 3848-3855. ［2］ Mathieu MG, Linley AJ, Reeder SP, et al. HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers［J］. Cancer Immun, 2010, 10: 2. ［3］ Mathieu MG, Knights AJ, Pawelec G, et al. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class Ⅰ/Ⅱ HAGEderived immunogenic peptides［J］. Cancer Immunol Immunother, 2007, 56(12): 1885-1895. ［4］ Cordin O, Banroques J, Tanner NK, et al. The DEAD box protein family of RNA helicases［J］. Gene, 2006, 367: 17-37. ［5］ Linley AJ, Mathieu MG, Miles AK, et al. The helicase HAGE expressed by malignant melanomainitiating cells is required for tumor cell proliferation in vivo［J］. J Biol Chem, 2012, 287(17): 13633-13643. ［6］ Mathieu MG, Miles AK, Ahmad M, et al. The helicase HAGE prevents interferonainduced PML expression in ABCB5+ malignant melanomainitiating cells by promoting the expression of SOCS1［J］. Cell Death Dis, 2014, 5: e1061. ［7］ Ambrosini G, Khanin R, Carvajal RD, et al. Overexpression of DDX43 mediates MEK inhibitor resistance through RAS upregulation in uveal melanoma cells［J］. Mol Cancer Ther, 2014, 13(8): 2073-2080. ［8］ Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer［J］. Nat Rev Cancer, 2005, 5(8): 615-625. ［9］ Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy［J］. Cancer Sci, 2009, 100(11): 2014-2021. ［10］ Riley CL, Mathieu MG, Clark RE, et al. Tumour antigentargeted immunotherapy for chronic myeloid leukaemia: is it still viable?［J］. Cancer Immunol Immunother, 2009, 58(9): 1489-1499. ［11］ Nagel H, Laskawi R, Eiffert H, et al. Analysis of the tumour suppressor genes, FHIT and WT1, and the tumour rejection genes, BAGE, GAGE1/2, HAGE, MAGE1, and MAGE3, in benign and malignant neoplasms of the salivary glands［J］. Mol Pathol, 2003, 56(4): 226-231. ［12］ Adams SP, Sahota SS, Mijovic A, et al. Frequent expression of HAGE in presentation chronic myeloid leukaemias［J］. Leukemia, 2002, 16(11): 2238-2242. ［13］ Condomines M, Hose D, Raynaud P, et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis［J］. J Immunol, 2007, 178(5): 3307-3315. ［14］ Liggins AP, Lim SH, Soilleux EJ, et al. A panel of cancertestis genes exhibiting broadspectrum expression in haematological malignancies［J］. Cancer Immun, 2010, 10: 8. ［15］ Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary［J］. Cancer Immun, 2004, 4: 1. ［16］ Akiyama Y, Komiyama M, Miyata H, et al. Novel cancertestis antigen expression on glioma cell lines derived from highgrade glioma patients［J］. Oncol Rep, 2014, 31(4): 1683-1690. ［17］ AbdelFatah TM, McArdle SE, Johnson C, et al. HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer［J］. Br J Cancer, 2014, 110(10): 2450-2461. ［18］ Shen L, Kondo Y, Guo Y, et al. Genomewide profiling of DNA methylation　reveals a class of normally methylated CpG island promoters［J］. PLoS Genet, 2007, 3(10): 2023-2036. ［19］ RomanGomez J, JimenezVelasco A, Agirre X, et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia［J］. Haematologica, 2007, 92(2): 153-162. ［20］ Chen Q, Lin J, Qian J, et al. The methylation status of the DDX43 promoter in Chinese patients with chronic myeloid leukemia［J］. Genet Test Mol Biomarkers, 2013, 17(6): 508-511. ［21］ Chen Q, Lin J, Yao DM, et al. Aberrant hypomethylation of DDX43 promoter in myelodysplastic syndrome［J］. Br J Haematol, 2012, 158(2): 293-296. ［22］ Lin J, Chen Q, Yang J, et al. DDX43 promoter is frequently hypomethylated and may predict a favorable outcome in acute myeloid leukemia［J］. Leuk Res, 2014, 38(5): 601-607.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

DDX43基因与肿瘤

DDX43 gene and tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价